Insider trading

Period: 120 months Stock: DGX Minimum amount: $1M × + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

64 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

64 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

64 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

64 decisions over 120 months Remove this filter
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
64 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
64 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

64 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
1 Sep 2026
Davis J. E. CEO and President
Sold on a plan
$2.43M 10,000 at 242.72
7.6%
Planned (10b5-1)
28 Aug 2026
PREVOZNIK MICHAEL E SVP & General Counsel
Sold on a plan 3×
$5.51M 22,677 at 243.11
37.6%
Planned (10b5-1)
4 Jun 2026
KUPPUSAMY KARTHIK SVP, Clinical Solutions
Sold on a plan
$1.63M 8,147 at 200.00
37.6%
Planned (10b5-1)
1 Jun 2026
Davis J. E. CEO and President
Sold on a plan
$1.94M 10,000 at 194.14
7.0%
Planned (10b5-1)
5 Mar 2026
Doherty Catherine T. EVP, Regional Businesses
Sold on a plan
$1.15M 5,558 at 206.21
7.6%
Planned (10b5-1)
2 Mar 2026
Davis J. E. CEO and President
Sold on a plan
$2.13M 10,000 at 212.52
7.9%
Planned (10b5-1)
13 Feb 2026
Doherty Catherine T. EVP, Regional Businesses
Sold on a plan 5×
$5.39M 26,165 at 206.15
27.8%
Planned (10b5-1)
10 Feb 2026
Plewman Patrick SVP for Diagnostic Services
Sold on a plan
$1.16M 5,662 at 204.00
26.9%
Planned (10b5-1)
25 Nov 2025
Davis J. E. CEO and President
Sold on a plan 3×
$10.59M 55,093 at 192.22
31.4%
Planned (10b5-1)
18 Nov 2025
DELANEY MARK E SVP & Chief Commercial Officer
Sold on a plan
$1.49M 7,946 at 187.35
51.3%
Sold half or more
23 Sep 2025
PREVOZNIK MICHAEL E SVP & General Counsel
Sold on a plan
$5.29M 28,288 at 187.12
42.6%
Planned (10b5-1)
30 Jul 2025
KUPPUSAMY KARTHIK SVP, Clinical Solutions
Sold on a plan 2×
$1.38M 8,269 at 167.40
43.7%
Planned (10b5-1)
2 Apr 2025
Davis J. E. CEO and President
Sold on a plan 15×
$6.60M 39,191 at 168.46
23.5%
Planned (10b5-1)
29 Nov 2024
PREVOZNIK MICHAEL E SVP & General Counsel
Sold at will 2×
$5.73M 35,146 at 163.07
47.7%
Not planned
27 Nov 2024
Doherty Catherine T. EVP, Regional Businesses
Sold at will 2×
$5.40M 33,103 at 162.99
32.6%
Not planned
6 Nov 2024
Deppe Michael J SVP, Corp. Controller & CAO
Sold at will 6×
$2.89M 18,755 at 154.05
34.9%
Not planned
29 Aug 2024
PREVOZNIK MICHAEL E SVP & General Counsel
Sold at will
$5.04M 32,551 at 154.97
45.8%
Not planned
28 Nov 2022
Doherty Catherine T. SVP, Regional Businesses
Sold, plan not stated 2×
$6.08M 40,765 at 149.18
37.6%
26 Oct 2022
Deppe Michael J VP, Corp. Controller & CAO
Sold, plan not stated
$2.25M 15,497 at 145.00
32.6%
25 May 2022
RUSCKOWSKI STEPHEN H Chairman, CEO and President
Sold, plan not stated 6×
$3.51M 24,891 at 140.89
6.9%
24 May 2022
RUSCKOWSKI STEPHEN H Chairman, CEO and President
Sold, plan not stated 2×
$39.57M 282,408 at 140.12
45.8%
23 May 2022
RUSCKOWSKI STEPHEN H Chairman, CEO and President
Sold, plan not stated 6×
$10.86M 77,466 at 140.17
18.8%
17 May 2022
PREVOZNIK MICHAEL E SVP & General Counsel
Sold, plan not stated
$7.08M 50,604 at 139.97
56.3%
Sold half or more
29 Nov 2021
Doherty Catherine T. SVP, Group Exec. Clin. Fran.
Sold, plan not stated 5×
$5.89M 37,565 at 156.81
35.3%
29 Jul 2021
RUSCKOWSKI STEPHEN H Chairman, CEO and President
Sold, plan not stated 2×
$1.34M 9,493 at 140.87
3.2%
28 Jul 2021
RUSCKOWSKI STEPHEN H Chairman, CEO and President
Sold, plan not stated
$19.58M 139,751 at 140.14
32.9%
27 Jul 2021
RUSCKOWSKI STEPHEN H Chairman, CEO and President
Sold, plan not stated
$4.59M 32,788 at 140.01
10.3%
27 Jul 2021
WILENSKY GAIL R Director
Sold, plan not stated 2×
$1.70M 12,222 at 139.30
40.6%
7 May 2021
Doherty Catherine T. SVP, Group Exec. Clin. Fran.
Sold, plan not stated
$1.19M 8,536 at 139.96
11.0%
5 May 2021
PREVOZNIK MICHAEL E SVP & General Counsel
Sold, plan not stated
$6.16M 44,939 at 137.00
52.8%
Sold half or more
24 Dec 2020
GUINAN MARK Executive Vice President & CFO
Sold, plan not stated 2×
$9.84M 81,756 at 120.37
52.6%
Sold half or more
23 Nov 2020
STANZIONE DANIEL Director
Sold, plan not stated 3×
$1.42M 11,223 at 126.30
28.4%
21 Oct 2020
Deppe Michael J VP, Corp. Controller & CAO
Sold, plan not stated 2×
$1.31M 10,450 at 125.00
29.4%
16 Oct 2020
RUSCKOWSKI STEPHEN H Chairman, CEO and President
Sold, plan not stated
$35.04M 291,997 at 120.00
55.1%
Sold half or more
14 Oct 2020
PREVOZNIK MICHAEL E SVP & General Counsel
Sold, plan not stated
$4.24M 35,591 at 119.00
47.0%
2 Sep 2020
Doherty Catherine T. SVP, Group Exec. Clin. Fran.
Sold, plan not stated 2×
$6.46M 58,392 at 110.60
46.0%
8 Jun 2020
GUINAN MARK Executive Vice President & CFO
Sold, plan not stated 3×
$8.51M 72,596 at 117.23
49.7%
8 Jun 2020
RING TIMOTHY M Director
Sold, plan not stated
$1.37M 11,730 at 116.60
36.4%
27 Apr 2020
RUSCKOWSKI STEPHEN H Chairman, CEO and President
Sold, plan not stated
$1.31M 11,717 at 112.01
4.7%
6 Mar 2020
RUSCKOWSKI STEPHEN H Chairman, CEO and President
Sold, plan not stated 5×
$25.93M 230,178 at 112.67
50.4%
Sold half or more
2 Jan 2020
Davis J. E. EVP, General Diagnostics
Sold, plan not stated 4×
$15.15M 143,537 at 105.57
79.7%
Sold half or more
27 Nov 2019
PREVOZNIK MICHAEL E SVP & General Counsel
Sold, plan not stated 3×
$4.79M 44,556 at 107.43
53.0%
Sold half or more
13 Jun 2019
RUSCKOWSKI STEPHEN H Chairman, President and CEO
Sold, plan not stated
$24.46M 244,565 at 100.00
53.4%
Sold half or more
13 Jun 2019
GUINAN MARK Executive Vice President & CFO
Sold, plan not stated
$7.30M 73,005 at 100.00
52.5%
Sold half or more
24 Apr 2019
Davis J. E. EVP, General Diagnostics
Sold, plan not stated
$4.52M 47,574 at 95.00
56.6%
Sold half or more
4 Apr 2019
Doherty Catherine T. SVP, Group Exec. Clin. Fran.
Sold, plan not stated 2×
$6.01M 66,382 at 90.59
49.6%
10 Jul 2018
Cunningham Everett SVP, Commercial
Sold, plan not stated
$4.52M 40,328 at 112.00
51.3%
Sold half or more
10 Jul 2018
PREVOZNIK MICHAEL E SVP & General Counsel
Sold, plan not stated
$3.48M 30,780 at 113.07
43.6%
2 Jul 2018
Cunningham Everett SVP, Commercial
Sold, plan not stated 6×
$7.47M 68,069 at 109.67
64.0%
Sold half or more
25 May 2018
RUSCKOWSKI STEPHEN H Chairman, President and CEO
Sold, plan not stated
$18.03M 168,490 at 107.00
46.9%
Showing 1–50 of 64. Page 1 of 2 Older →